Epoetins: differences and their relevance to immunogenicity
- 1 January 2003
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 19 (5), 430-432
- https://doi.org/10.1185/030079903125002063
Abstract
Recombinant human erythropoietin (epoetin) is a highly active molecule and as such is used at very low therapeutic concentrations that require stabilisation. Commercially available epoetins differ in the stabilisers used in their formulations, which result in variations between epoetin preparations in storage and handling requirements. The stability and solubility of the epoetins are also affected by differences in the carbohydrate moieties that exist between them. However, it is the difference in stabilising agents that is thought to be the major cause of the upsurge in pure red cell aplasia (PRCA) cases observed predominantly with one epoetin alfa formulation, Eprex (Johnson & Johnson). In 1998 the European formulation of Eprex was changed with the replacement of human serum albumin (HSA), by polysorbate 80 and glycine. This formulation change coincided with an increased incidence of PRCA. In contrast, the incidence of PRCA has remained low with other HSA-containing epoetin alfa products and with epoetin beta. Therefore, it appears that the change in Eprex formulation has resulted in reduced protein stability and increased immunogenicity.Keywords
This publication has 7 references indexed in Scilit:
- Pure red-cell aplasia due to anti-erythropoietin antibodiesNephrology Dialysis Transplantation, 2003
- Pure Red-Cell Aplasia and Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Drug-Induced Autoimmune Red-Cell AplasiaNew England Journal of Medicine, 2002
- Comparison of impact of the different hydrophilic carriers on the properties of piperazine-containing drug.European Journal of Pharmaceutics and Biopharmaceutics, 2001
- Epoetin alpha and beta in their erythropoetin isoform compositions and biological propertiesBritish Journal of Haematology, 1998
- Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin betaClinical Pharmacology & Therapeutics, 1991